文献速递妇科

阿帕替尼用于复发性上皮性卵巢癌患者的II期研究

A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2017-12-18

这项多中心、开放标签、单臂II期研究纳入29例复发性铂耐药经治上皮性卵巢癌患者,口服阿帕替尼500mg每日一次。28例可评估疗效者中,客观缓解率为41.4%(95%CI 23.3%-59.4%),疾病控制率为68.9%(95%CI 52.1%-85.8%),中位无进展生存期5.1个月(95%CI 3.8-6.5个月),中位总生存期14.5个月(95%CI 12.4-16.4个月)。作者认为阿帕替尼500mg每日一次口服是可行的治疗选择,需要开展纳入更多患者的多中心前瞻性研究。

要点

  • 复发性铂耐药经治上皮性卵巢癌患者口服阿帕替尼500mg每日一次,客观缓解率41.4%。
  • 中位无进展生存期5.1个月,中位总生存期14.5个月,疾病控制率68.9%。
  • 常见治疗相关不良事件为手足综合征51.7%、高血压34.6%、恶心呕吐31.0%。

核心结论

  • 阿帕替尼500mg每日一次口服是复发性铂耐药经治上皮性卵巢癌患者的可行治疗,需要开展纳入更多患者的多中心前瞻性研究。

研究设计与样本

  • 多中心、开放标签、单臂II期研究,纳入29例复发性铂耐药经治上皮性卵巢癌患者,均接受阿帕替尼500mg每日一次口服。
  • 主要终点为按MASS标准的客观缓解率,次要终点为无进展生存期、总生存期、疾病控制率、安全性和耐受性。
  • 治疗持续至疾病进展或阿帕替尼不可耐受,中位治疗时间36.8周(范围13-64.8周),中位随访时间12个月。

主要发现

  • 28例可评估疗效,客观缓解率为41.4%(95%CI 23.3%-59.4%),疾病控制率为68.9%(95%CI 52.1%-85.8%)。
  • 中位无进展生存期为5.1个月(95%CI 3.8-6.5个月),中位总生存期为14.5个月(95%CI 12.4-16.4个月)。
  • 最常见治疗相关不良事件为手足综合征51.7%、高血压34.6%、恶心呕吐31.0%。
  • 3例患者无显著毒性,9例患者发生3级治疗相关不良事件。

关键数值与推荐

  • 客观缓解率按MASS标准评估,为41.4%(95%CI 23.3%-59.4%)。
  • 疾病控制率为68.9%(95%CI 52.1%-85.8%)。
  • 中位无进展生存期为5.1个月(95%CI 3.8-6.5个月),中位总生存期为14.5个月(95%CI 12.4-16.4个月)。

临床怎么用

  • 作者认为阿帕替尼500mg每日一次口服是复发性铂耐药经治上皮性卵巢癌患者的可行治疗。
  • 作者提出需要开展纳入更多患者的多中心前瞻性研究。

局限性

  • 作者提出需要开展纳入更多患者的多中心前瞻性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Antiangiogenic treatments have been implicated to play a major role in epithelial ovarian cancer (EOC). Apatinib, a novel oral antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGFR2), is currently being studied in different tumor types and is already used in gastric adenocarcinoma. This study was performed to assess the efficacy and safety of apatinib in patients with recurrent, pretreated EOC. PATIENTS AND METHODS: Patients with recurrent, platinum-resistant, pre-treated EOC who failed available standard chemotherapy were enrolled. Apatinib was administered as 500mg daily. Primary objective is the overall response rate (ORR) according to MASS criteria. Secondary objectives are progression free survival (PFS), overall survival (OS), disease control rate (DCR), safety and tolerability. The treatment duration is until disease progression or intolerability of apatinib. RESULTS: 29 eligible patients were enrolled in this multicenter, open-label, single arm study and received apatinib for a median of 36.8weeks (range 13-64.8weeks). Median follow-up time was 12months. 28 patients were eligible for efficacy analysis. ORR is 41.4% (95% confidence interval (CI), 23.3%-59.4%). DCR is 68.9% (95% CI, 52.1%-85.8%). Median PFS is 5.1months (95% CI, 3.8m-6.5m). Median OS is 14.5months (95% CI, 12.4m-16.4m). The most common treatment-related adverse events (AEs) were hand-foot syndrome (51.7%), hypertension (34.6%), nausea and vomiting (31.0%). 3 patients had no significant toxicity. 9 patients experienced grade 3 treatment-related AEs. CONCLUSIONS: Apatinib 500mg daily p.o. is a feasible treatment in patients with recurrent, platinum-resistant, pretreated EOC. Multi-center prospective studies enrolling more patients are needed.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Miao M, Deng G, Luo S, et al. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer. Gynecol Oncol. 2017. PMID: 29248198. doi:10.1016/j.ygyno.2017.12.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。